Home » Ordering Information

Aggrastat® injection is supplied in three product formats

AGGRASTAT® Injection Pre-mixed (HCPCS code J3246) is a clear, non-preserved, sterile solution premixed in a vehicle made iso-osmotic with 0.9% sodium chloride.

In 2021, Medicure Pharma reintroduced the AGGRASTAT® 5MG/100ML Bag (NDC: 25208-0002-01). It is the same concentration, ready-to-use- format, storage, and has the same stability properties and price as the AGGRASTAT® 5MG/100ML Vial (NDC: 25208-0002-03). The 5MG/100ML vial format will no longer be manufactured. The 5MG/100ML bag will replace the 5MG/100ML vial.

Product Format Product Details
NDC Concentration Total Amount
15 mL Bolus Vial 25208-0001-04 250 mcg/mL 3.75 mg/15 mL
100 mL Bag 25208-0002-01 50 mcg/mL 5 mg/100 mL
250 mL Bag 25208-0002-02 50 mcg/mL 12.5 mg/250 mL


How to order

  • AGGRASTAT® is available through normal distribution at your wholesaler.
  • For immediate supply, AGGRASTAT® is available as a drop shipment via Express Overnight Delivery. It is important to provide your wholesaler with updated demand forecasts for AGGRASTAT®.
Wholesaler Item Number
3.75 mg/15ml
Pre-mixed Bolus Vial		 5 mg/100 ml
Pre-mixed Bag		 12.5 mg/250 ml
Pre-mixed Bag
AmerisourceBergen Drug Corporation 10169784 10261079 10040778
Cardinal Health, lnc. 5293881 4073318 4073334
McKesson Corporation 3590874 1469677 1480433
Morris & Dickson Company, LLC 856963 930917 859645


Authorized Distributors of Record:

  • AmerisourceBergen Drug Corporation
  • Borschow Hospital & Medical Supplies, Inc.
  • Cardinal Health, Inc.
  • Cesar Castillo, Inc.
  • Dakota Drug, Inc.
  • DMS Pharmaceutical Group, Inc.
  • HD Smith Wholesale Drug Company
  • McKesson Corporation
  • Morris & Dickson Company, LLC
  • Smith Drug Company
Storage and handling of AGGRASTAT®

Store AGGRASTAT® at controlled room temperature, 25 °C (77 °F) with excursions permitted between 15–30 °C (59–86 °F). Do not freeze. Protect from light during storage.

Product return and replacement

Please download our Product Return and Replacement Form or email aggrastat@medicure.com to learn more.


Important Safety Information

Indication:

Aggrastat® is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).

Contraindications:

  • Known hypersensitivity to any component of Aggrastat®.
  • History of thrombocytopenia with prior exposure to Aggrastat®.
  • Active internal bleeding, or history of bleeding diathesis, major surgical procedure or severe physical trauma within the previous month.

Warnings and Precautions:

  • Aggrastat® can cause serious bleeding. Most bleeding associated with Aggrastat® occurs at the arterial access site for cardiac catheterization. Minimize the use of traumatic or potentially traumatic procedures such as arterial and venous punctures, intramuscular injections, nasotracheal intubation, etc. Concomitant use of fibrinolytics, anticoagulants and antiplatelet drugs increases the risk of bleeding. If bleeding cannot be controlled, discontinue Aggrastat®.
  • Thrombocytopenia: discontinue Aggrastat® and heparin.

Adverse Reactions:

  • Bleeding is the most commonly reported adverse reaction.

For additional information, refer to the full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.FDA.gov/medwatch
or call 1-800-FDA-1088.